Safety and efficacy of laxatives after major abdominal surgery: systematic review and meta-analysis

N. N. Dudi-Venkata¹ ², W. Seow², H. M. Kroon¹, S. Bedrikovetski², J. W. Moore¹ ², M. L. Thomas¹ ² and T. Sammour¹ ²

¹ Colorectal Unit, Department of Surgery, Royal Adelaide Hospital, and ² Discipline of Surgery, Faculty of Health and Medical Sciences, School of Medicine, University of Adelaide, Adelaide, South Australia, Australia

Correspondence to: Dr N. N. Dudi-Venkata, 5E 330 - A, Desk -1, Colorectal Unit, Department of Surgery, Royal Adelaide Hospital, Port Road, Adelaide, South Australia 5000, Australia (e-mail: drnags3@gmail.com; surgnags)

Introduction

Recovery of gastrointestinal function is often delayed after major abdominal surgery, leading to postoperative ileus (POI)¹. For patients experiencing POI, it is a source of significant morbidity and discomfort, causing vomiting, abdominal distension and intolerance to diet, and often leading to invasive interventions such as insertion of a nasogastric tube² ³. Postoperative complications such as POI can have a significant impact on patient outcome, in terms of short-term recovery, long-term survival, and quality of life⁴ ⁶. Healthcare expenditure is almost twice as high when patients develop POI compared with that for patients who do not⁷ ⁹, and there is evidence that 91 per cent of these increased costs relate directly to the patient’s immediate postoperative stay⁷.

Since the implementation of enhanced recovery protocols (ERPs), the management of patients undergoing abdominal surgery has improved, with a reduction in the incidence of complications¹⁰ ¹⁶. However, despite the widespread adoption of ERPs, the incidence of POI remains high at around 10–30 per cent, with delayed return of gastrointestinal function continuing to be a common barrier to discharge from hospital⁸ ¹⁷ ¹⁹. One possible reason for this could be because of a complex, intricate, and as yet incompletely defined relationship
between the neuroinflammatory, vagal and drug-induced processes underlying the pathophysiology of POI\cite{20,21}. Multimodal strategies have been employed to improve the return of gastrointestinal function after surgery, including the routine use of postoperative laxatives\cite{22,23}. The recommendations for laxative use are varied in different international ERP protocols, with only weak evidence quoted to support their efficacy\cite{24}. In addition, published data on the safety of postoperative laxatives in this setting are limited, in particular with regard to anastomotic leak.

This systematic review aimed to assess the safety and efficacy of laxative use after major abdominal surgery.

**Methods**

The study protocol was registered prospectively with the PROSPERO database of systematic reviews (CRD42019126282). PRISMA guidelines\cite{25} were used for conducting and reporting the results of this study.

**Search strategy**

Two independent reviewers performed a systematic search of the MEDLINE (1946 to 21 May 2019), Embase (1974 to 21 May 2019), Cumulative Index to Nursing and Allied Health Literature (CINAHL) (EBSCOhost) databases (1974 to 21 May 2019), and the Cochrane Database of Systematic Reviews, Cochrane Clinical Trials Register, and Database of Abstracts on Reviews and Effectiveness. All ‘Primary Registries’ listed in the WHO Registry Network (including ClinicalTrials.gov) were searched for ongoing (unpublished) RCTs (searched on 22 May 2019). The detailed search strategy is shown in Table S1 (supporting information). Medical subject headings (MeSH) and keyword search terms related to ‘ERAS’, ‘recommendations’, ‘laxatives’, ‘abdominal’, ‘surgery’, ‘prevention’, ‘postoperative’, ‘ileus’ and ‘gastrointestinal 2’ (GI-2) were used. Unpublished data were also sought from authors of trials listed in the registry. The search was limited to studies published in the English language. The last search update was on 22 May 2019.

**Eligibility criteria**

Studies were included if they were RCTs conducted in patients aged more than 16 years undergoing elective open or minimally invasive major abdominal surgery, and specifically assessed the effect of laxatives on the return of gastrointestinal function, defined by time to passage of stool or using a validated measure such as GI-2 or GI-3. GI-2 is a composite measure of tolerance to solid diet for 24 h (no vomiting) and passage of stool, whereas GI-3 is a composite measure of tolerance to solid diet for 24 h (no vomiting) and passage of flatus\cite{26}. Eligible articles with a description of interventions directed towards stimulation of bowel motility, prevention of POI or reducing its duration, or facilitating the return of gastrointestinal function after surgery were included in the final analysis. All gastrointestinal (colorectal, gastric, small bowel, hepatic, pancreatic resection), urological (nephrectomy, cystectomy, prostatectomy) and gynaecological (uterus and ovary resection, pelvic floor reconstruction) operations, undertaken for any indication, were considered as major abdominal surgery. Studies with quasirandomized, prospective and retrospective design, and case–control studies were excluded.

**Study selection**

All identified titles and abstracts were reviewed independently by two investigators. This was followed by a further review of the full texts of potentially relevant studies. Bibliographies of relevant articles also underwent a manual cross-reference search to identify any other studies that had been missed in the search. Any potential differences over study selection were resolved by consensus and, if needed, adjudication was undertaken by a third reviewer.

**Data collection process**

Data of all included studies were extracted independently by two reviewers using a standard data extraction form. Outcome measures data, including GI-2 or GI-3, time taken to passage of first stool, time taken to tolerance of solid food, time taken to first flatus, length of hospital stay, postoperative complications, adverse drug effects and readmission to hospital, were extracted. In addition to the measured outcomes, other data related to general study characteristics, including author name, country of origin, year of study, study type, patient population, number of patients in control and intervention arm, site of surgery, type of intervention (laxatives) and route of administration, were also extracted. All the data were cross-checked at the end, and any discrepancies in the extraction of the data were resolved by the third reviewer.

**Risk of bias in individual studies**

The Cochrane Collaboration risk-of-bias tool\cite{27} was used independently by two authors to assess the methodological
quality of individual RCTs. A consensus was sought for any disagreements.

Assessment of quality of evidence

Quality of evidence and summary of findings were tabulated using the GRADEpro Guideline Development Tool (McMaster University, Hamilton, Ontario, Canada).

Statistical analysis

JBI SUMARI online software (https://www.jbisumari.org/) was used for quantitative analysis of aggregated data. An intention-to-treat methodology was adopted. Mean estimates were calculated by the method proposed by Wan et al.\textsuperscript{28}. Effect estimates are reported as odds ratios (ORs) and weighted mean differences (MDs) with 95 per cent c.i. for dichotomous and continuous outcomes respectively. Considering the heterogeneity between the studies, pooled estimates of effect were calculated using a random-effects model. Statistical significance was set at \( P < 0.050 \) for the degree of heterogeneity, which was determined by the \( \chi^2 \) test. Heterogeneity measured by the \( I^2 \) statistic was perceived as considerable when the \( I^2 \) value was above 75 per cent\textsuperscript{29}.

To decrease potential bias introduced by diverse indications and surgical methods, a planned subgroup analysis was performed on primary and secondary outcomes for patients who underwent colorectal surgery.

Results

The literature search identified 323 studies. After removal of 13 duplicates, a further 280 studies were excluded after screening by title and abstract. Four authors of unpublished studies from trial registries were contacted via e-mail to enquire about the progress of their study and the relevant results, if any. One author responded and confirmed that the trial was not yet completed. In addition, authors of all the RCTs included in the meta-analysis were contacted, requesting raw trial data to explore finer details of the trial further, but none responded.

Thirty studies met the prespecified inclusion criteria and were evaluated by full-text analysis. This analysis initially yielded six RCTs for inclusion, but one\textsuperscript{30} of these was excluded on further review as participants in this study received baseline laxative (docusate sodium) in both intervention and control groups. Hence, five RCTs\textsuperscript{31–35} were finally selected for inclusion (Fig. 1).

Characteristics of included studies

The five included RCTs\textsuperscript{31–35} were published between 2007 and 2011, and included 416 patients (209 (range 10–100) in the laxative group and 207 (10–100) in the placebo group). Study characteristics, interventions and outcomes are summarized in Tables 1 and 2. The studies were conducted in six countries. Three RCTs\textsuperscript{31,34,35} involved patients with colorectal disease, and the other two were in patients undergoing hysterectomy\textsuperscript{32} and hepatic resection\textsuperscript{33}.

Cochrane Collaboration risk-of-bias assessment

All seven components were assessed as low risk for three RCTs\textsuperscript{33–35}, but there was a high risk of attrition bias for two trials\textsuperscript{31,32} owing to incomplete outcome data. Only a small number of trials were included in this study, so a funnel plot for potential publication bias was not generated as this would not have enough data points to be meaningful. Summary graphs for risk of bias are shown in Figs S1 and S2 (supporting information).

Study interventions

The most tested laxatives were magnesium oxide and bisacodyl. Oral magnesium oxide was the intervention used in two studies\textsuperscript{31,33}, bisacodyl in two studies (one per rectum\textsuperscript{34} and one orally\textsuperscript{35}), and disodium phosphate along with magnesium oxide in one study\textsuperscript{32} (Table 1). Laxative regimens differed in terms of the day of starting care in the control arm (no placebo).

Quantitative analysis

Return of gastrointestinal function

None of the studies reported GI-2. One study\textsuperscript{35} reported significantly shorter time to GI-3 in the laxative versus control group (median 3 (range 1–12.3) versus 3.7 (1.7–10.7) days respectively; \( P = 0.007 \)). Time to the passage of stool was reported by all five studies\textsuperscript{31–35}; there was a statistically significant difference for laxatives compared with control (MD –0.83 (95 per cent c.i. –1.39 to –0.26) days; \( P = 0.004 \)), although there was significant
heterogeneity between the studies for this outcome ($I^2 = 94$ per cent; $P < 0.001$) (Fig. 2a).

Time to passage of flatus

Time to passage of flatus was reported by three studies$^{31,33,35}$; there was no statistically significant difference between laxatives and control (MD $−0.17$ (95 per cent c.i. $−0.59$ to $0.25$) days; $P = 0.432$). There was significant heterogeneity between the studies for this outcome ($I^2 = 87$ per cent; $P < 0.001$) (Fig. 2b).

Time to a tolerance of diet

Three studies$^{33−35}$ reported time to a tolerance of diet; there was no significant difference between the laxatives
and control group (MD −0.01 (95 per cent c.i. −0.12 to 0.10) days; \(P=0.865\)). There was no significant heterogeneity between the studies for this outcome \(I^2=0\) per cent; \(P=0.677\) (Fig. 2i).

**Length of hospital stay**

Length of hospital stay was reported by all studies\(^{31–35}\); there was no significant difference between the laxatives and control group (MD 0.01 (95 per cent c.i. −1.36 to 1.38) days; \(P=0.992\)). There was significant heterogeneity between the studies for this outcome \(I^2=92\) per cent; \(P<0.001\) (Fig. 2d).

**Postoperative complications**

Pooled analysis was not done on these outcomes as the data available in the included studies were limited. Superficial surgical-site infections were reported in two (20 per cent) of ten patients in the control group in one study\(^{34}\), whereas another\(^{33}\) reported one death (3 per cent) of 31 patients in the laxative group from cardiac arrest on the second postoperative day; however, the complication profile was similar in both groups in other reports\(^{32,33}\). No significant difference in surgical complications (anastomotic leak, surgical-site infection, abdominal fascia dehiscence, postoperative bleeding) or non-surgical morbidity (pneumonia, cardiac failure, pulmonary embolism, renal failure, urinary tract infection) was reported in another RCT\(^{35}\); overall surgical morbidity in this study was 23.1 per cent, whereas non-surgical complications occurred in 13 per cent of all patients.

**Subgroup analysis**

In the three studies\(^{31,34,35}\) with only colorectal patients, no significant difference was found in time to passage of stool between the laxatives and control group (MD −0.64 (95 per cent c.i. −1.63 to 0.34) days; \(P=0.201\)). Heterogeneity was significant for this outcome \(I^2=92\) per cent; \(P<0.001\) (Fig. 3a). Length of hospital stay in the laxatives and control group showed no significant difference (MD −0.29 (−2.36 to 1.79) days; \(P=0.787\)). There was no heterogeneity between studies for this outcome \(I^2=0\) per cent; \(P=0.548\) (Fig. 3b). Anastomotic leak rates for these studies ranged between 0 per cent in both groups\(^{34\text{a}}\), 8.3 versus 6.3 per cent \((P>0.99)\)\(^{31}\), and 8.4 versus 4.7 per cent \((P=0.365)\)\(^{35}\) in the laxative versus control group respectively.

---

**Table 2 Characteristics of study interventions and outcomes**

| Reference               | Intervention                                      | Control       | Primary                                                                 | Secondary                  |
|-------------------------|---------------------------------------------------|---------------|------------------------------------------------------------------------|----------------------------|
| Andersen et al.\(^{31}\) | Magnesium oxide 1 g orally, twice daily           | Placebo       | Time to first defaecation (h)                                          | LOS (days)                 |
|                         | D0 at 18.00 hours D1–7 twice daily                |               | Time to passage of flatus (h)                                          |                            |
|                         |                                                   |               | Cumulative median no. of orally consumed drinks, supplementary protein|                            |
|                         |                                                   |               | drinks and solid foods on D0, D2–3                                     |                            |
| Hansen et al.\(^{32}\)  | Magnesium oxide 1 g D0 6 h after surgery          | Placebo       | Time to first defaecation (h)                                          | Pain score                 |
|                         | D1 twice daily                                    |               |                                                                         |                            |
| Hendry et al.\(^{33}\)  | Magnesium oxide 1 g twice daily D0 to day of discharge | No placebo Standard of care | Time to first defaecation (days)                                       | Oral nutritional intake D1–3 |
|                         |                                                   |               | Time to passage of flatus (days)                                       | LOS (days)                 |
| Wiriyakosol et al.\(^{34}\) | Bisacodyl suppositories 10 mg once daily to twice daily D3 | Placebo       | Time to first defaecation (days)                                       | Time to passage of flatus   |
|                         | If no defaecation after first dose, second dose  |               |                                                                         | (days)                     |
|                         | administered 12 h later                           |               |                                                                         | LOS (days)                 |
| Zingg et al.\(^{35}\)   | Bisacodyl 10 mg orally, twice daily D–1 to D3     | Placebo       | Time to first defaecation (days)                                       | LOS (days)                 |
|                         |                                                   |               | Time to passage of flatus (days)                                       |                            |
|                         |                                                   |               | Time to tolerance of solid diet (days)                                 |                            |

LOS, length of hospital stay; D0, day of surgery; D1, day 1 after surgery; D–1, 1 day before surgery.
Fig. 2 Forest plots comparing time to passage of stool and flatus, time to tolerate diet and length of hospital stay in laxatives and control groups, all studies

|                | Time to passage of stool | Time to passage of flatus | Time to tolerate diet | Length of hospital stay |
|----------------|--------------------------|---------------------------|-----------------------|------------------------|
| **Reference**  | **Time to stool (days)** | **Time to flatus (days)** | **Time to tolerate diet (days)** | **Length of stay (days)** |
|                | Laxatives | No laxatives | MD (days) | Weight (%) | MD (days) | Laxatives | No laxatives | MD (days) | Weight (%) | MD (days) | Laxatives | No laxatives | MD (days) | Weight (%) | MD (days) |
| Andersen et al. | 2.17(0.97) | 1.83(0.65) | 19.77 | 0.34 (0.07, 0.75) |
| Hendry et al.   | 1.57(0.49) | 2.73(0.34) | 21.45 | –1.16 (–1.36, –0.96) |
| Zingg et al.    | 4.04(0.48) | 5.04(0.48) | 21.29 | –1.00 (–1.23, –0.77) |
| Wiriyakosol et al | 3(0)    | 4.1(0.74) | 19.28 | –1.10 (–1.56, –0.64) |
| Zingg et al.    | 3.1(1.9) | 4.3(2.1) | 18.21 | –1.20 (–1.76, –0.64) |
| **Total**       |           |           | 100.00 | –0.83 (–1.39, –0.26) |
| **Heterogeneity:** | \( \chi^2 = 3.86 \) | \( \chi^2 = 34.34 \) | \( \chi^2 = 43.34 \) | \( \chi^2 = 43.34 \) |
| **Test for overall effect:** | \( Z = –2.85 \), \( P = 0.004 \) | \( Z = –10.78 \), \( P = 0.001 \) | \( Z = –2.45 \), \( P = 0.012 \) | \( Z = –3.40 \), \( P = 0.001 \) |

Favours laxatives Favours no laxatives

|                | Time to passage of flatus | Time to tolerate diet | Length of hospital stay |
|----------------|--------------------------|-----------------------|------------------------|
| **Reference**  | **Time to flatus (days)** | **Time to tolerate diet (days)** | **Length of stay (days)** |
|                | Laxatives | No laxatives | MD (days) | Weight (%) | MD (days) | Laxatives | No laxatives | MD (days) | Weight (%) | MD (days) |
| Andersen et al. | 1.08(0.57) | 0.83(0.41) | 34.06 | 0.25 (0.00, 0.50) |
| Hendry et al.   | 2.63(0.36) | 3.04(0.48) | 35.47 | –0.37 (–0.57, –0.17) |
| Zingg et al.    | 1.9(1.1) | 2.3(1.4) | 30.47 | –0.40 (–0.75, –0.05) |
| **Total**       |           |           | 100.00 | –0.17 (–0.59, 0.25) |
| **Heterogeneity:** | \( \chi^2 = 12.12 \) | \( \chi^2 = 16.54 \) | \( \chi^2 = 22.42 \) | \( \chi^2 = 22.42 \) |
| **Test for overall effect:** | \( Z = –0.79 \), \( P = 0.432 \) | \( Z = –0.17 \), \( P = 0.10 \) | \( Z = –0.01 \), \( P = 0.01 \) | \( Z = –0.01 \), \( P = 0.01 \) |

Favours laxatives Favours no laxatives

|                | Time to tolerate diet | Length of hospital stay |
|----------------|-----------------------|------------------------|
| **Reference**  | **Time to tolerate diet (days)** | **Length of stay (days)** |
|                | Laxatives | No laxatives | MD (days) | Weight (%) | MD (days) | Laxatives | No laxatives | MD (days) | Weight (%) | MD (days) |
| Hendry et al.   | 0.75(0.24) | 0.75(0.24) | 95.87 | 0.00 (–0.11, 0.11) |
| Wiriyakosol et al | 5.4(0.97) | 5.7(0.48) | 2.77 | –0.30 (–0.97, 0.37) |
| Zingg et al.    | 5.3(3.6) | 5.4(3.3) | 1.36 | –0.10 (–1.06, 0.86) |
| **Total**       |           |           | 100.00 | –0.01 (–0.12, 0.10) |
| **Heterogeneity:** | \( \chi^2 = 0 \). | \( \chi^2 = 0.78 \) | \( \chi^2 = 0.78 \) | \( \chi^2 = 0.78 \) |
| **Test for overall effect:** | \( Z = –0.17 \), \( P = 0.865 \) | \( Z = –0.01 \), \( P = 0.01 \) | \( Z = –0.01 \), \( P = 0.01 \) | \( Z = –0.01 \), \( P = 0.01 \) |

Favours laxatives Favours no laxatives

a Time taken to passage of stool; b time taken to passage of flatus; c time to tolerate diet; d length of stay in hospital. Values in parentheses are 95 per cent c.i. unless indicated otherwise; *values are mean(s.d.). An inverse-variance random-effects model was used for meta-analysis. Weighted mean differences (MDs) are shown with 95 per cent confidence intervals.
a Time to passage of stool

| Reference          | Laxatives | No laxatives | MD (days) | Weight (%) | MD (days) |
|--------------------|-----------|--------------|-----------|------------|-----------|
| Andersen et al.21   | 2·17(0·97)| 1·83(0·65)   | –0·34     | 34·02      | 0·34(–0·07, 0·75) |
|Wiriyakosol et al.24| 3(0)     | 4·1(0·74)    | –1·10     | 33·54      | –1·10(–1·56, –0·64) |
|Zingg et al.25      | 3·1(2·1) | 4·3(2·1)     | –1·20     | 32·44      | –1·20(–1·76, –0·64) |
|Total               |           |              | –0·64     | 100·00     | –0·64(–1·63, 0·34) |

Heterogeneity: $τ^2=0·7$, $χ^2=28·72$, 2 d.f., $P<0·001$, $I^2=92\%$

Test for overall effect: $Z=–1·28$, $P=0·201$ –3 –2 –1 0 1 2 3 4

Favours laxatives Favours no laxatives

b Length of hospital stay

| Reference          | Laxatives | No laxatives | MD (days) | Weight (%) | MD (days) |
|--------------------|-----------|--------------|-----------|------------|-----------|
| Andersen et al.21   | 9·25(6·69)| 9·6(6·33)    | –0·25     | 45·09      | 0·25(–2·84, 3·34) |
|Wiriyakosol et al.24| 8·5(2·7)  | 10·4(5·2)   | –1·90     | 32·69      | –1·90(–5·53, 1·73) |
|Zingg et al.25      | 16(12)    | 15(19)      | 1·00      | 22·22      | 1·00(–3·40, 5·40) |
|Total               |           |              |           | 100·00     | –0·29(–2·36, 1·79) |

Heterogeneity: $τ^2=0$, $χ^2=1·2$, 2 d.f., $P=0·548$, $I^2=0\%$

Test for overall effect: $Z=–0·27$, $P=0·787$ –4 –3 –2 –1 0 1 2 3 4

Favours laxatives Favours no laxatives

a Time taken to passage of stool; b length of stay in hospital. Values in parentheses are 95 per cent c.i. unless indicated otherwise; *values are mean(s.d.). An inverse-variance random-effects model was used for meta-analysis. Weighted mean differences (MDs) are shown with 95 per cent confidence intervals.

**GRADE assessment for quality of evidence**

Using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) criteria, the overall quality of evidence for time taken to defaecation and to tolerate diet was low, whereas it was very low for time taken to pass flatus and length of hospital stay (Table S2, supporting information).

**Discussion**

This meta-analysis of all available RCTs evaluating laxatives after major abdominal surgery demonstrates that time to passage of stool is shorter with laxative use. However, there was significant heterogeneity between studies for this outcome measure, and time to passage of flatus, time to tolerance of diet and length of stay in hospital were unaffected. There were insufficient data to draw conclusions on the safety profile of laxatives used in this setting.

The effect of laxatives on bowel motility depends on the type and mechanism of action. Some laxatives (such as sennosides) work by stimulating gut activity and others (such as polyethylene glycol) by osmotic distension of the bowel lumen. A distended colon is more likely to initiate colonic contractions leading to a bowel movement than a non-distended, empty colon16,37. There is also evidence of a postoperative ‘brake’ system in or around the rectosigmoid colon that acts as a physiological sphincter by causing retrograde contractions and inhibiting normal passage of enteric contents38. It is plausible that giving laxatives per rectum could counteract this pathophysiological effect, initiating an antegrade bowel movement. Published evidence of the use of laxatives to improve gastrointestinal function after surgery dates back to the late 1990s39–42. ERP guidelines commonly recommend using laxatives to stimulate bowel motility after surgery; however, these recommendations are not uniform and vary geographically. Moreover, the evidence behind these recommendations is quoted to be weak in several guidelines24.

The data in this review suggest there may be a benefit of laxatives after abdominal surgery. However, although earlier passage of stool is typically associated with earlier
recovery of gastrointestinal function, interpretation is limited when measured in isolation. Most validated measures of gastrointestinal recovery are composite scores including other relevant parameters. It is interesting that there was no difference in time to tolerance of diet or time to discharge in the present meta-analysis. This could mean that laxatives result in a stimulated bowel movement, but not in improved recovery after surgery. Another potential explanation could be that, although well patients in the intervention arm passed stool earlier overall, there was no difference in rates of POI in the subset of patients, leading to a similar, longer, hospital stay overall in both groups. As rates of POI and validated outcome measures such as GI-2 were not recorded in most studies, it is not possible to assess this further.

This review has several limitations, including the significant heterogeneity of the included studies, lack of validated outcome measures, small sample sizes, and variation in the types of operation performed and types of intervention used. In addition, data on complications were not adequate for meta-analysis.

Given that most common laxatives are cheap medications with a favourable toxicity profile, their use deserves further exploration in the postoperative setting. To this end, further higher-powered RCTs are required with a specific focus on validated measures of gastrointestinal recovery and accurate collection of complications data (such as anastomotic leak). It remains unclear whether laxatives should be used after surgery in selected patients after abdominal surgery, or as a routine in all postoperative patients. The type and dose of laxative also varied between the included studies, and there may be a role for using a combination of laxatives with different mechanisms of action (both direct activity of bowel function and osmotic distension), as this is common in other aspects of enhanced recovery protocols (for example, multimodal pre-emptive analgesia and antiemetics). The STIMULAX RCT (Australian New Zealand Clinical Trials Registry number ACTRN12618001261202), which is currently recruiting patients undergoing colorectal surgery, should address some of these questions.

Acknowledgements

N.N.D.-V. was supported by a Royal Australasian College of Surgeons W. G. Norman Research Scholarship (RACS ID 187648) and a Medtronic Colorectal Research Fellowship Supplementary Scholarship (a1753714).

Disclosure: The authors declare no conflict of interest.

References

1 Vather R, Trivedi S, Bisset I. Defining postoperative ileus: results of a systematic review and global survey. J Gastrointest Surg 2013; 17: 962–972.
2 Vather R, Bisset I. Management of prolonged post-operative ileus: evidence-based recommendations. ANZ J Surg 2013; 83: 319–324.
3 Okamoto A, Kohama K, Aoyama-Ishikawa M, Yamashita H, Fujisaki N, Yamada T et al. Intraperitoneally administered, hydrogen-rich physiologic solution protects against postoperative ileus and is associated with reduced nitric oxide production. Surgery 2016; 160: 623–631.
4 Scarborough JE, Schumacher J, Kent KC, Heise CP, Greenberg CC. Associations of specific postoperative complications with outcomes after elective colon resection: a procedure-targeted approach toward surgical quality improvement. JAMA Surg 2017; 152: e164681.
5 Khuri SF, Henderson WG, DePalma RG, Mosca C, Healey NA, Kumbhani DJ. Participants in the VA National Surgical Quality Improvement Program. Determinants of long-term survival after major surgery and the adverse effect of postoperative complications. Ann Surg 2005; 242: 326–341.
6 Silber JH, Rosenbaum PR, Trudeau ME, Chen W, Zhang X, Kelz RR et al. Changes in prognosis after the first postoperative complication. Med Care 2005; 43: 122–131.
7 Goldstein JL, Matuszewski KA, Delaney CP, Senagore A, Chiao EF, Shah M et al. Inpatient economic burden of postoperative ileus associated with abdominal surgery in the United States. PêT 2007; 32: 82–90.
8 Iyer S, Saunders WB, Stenkowski S. Economic burden of postoperative ileus associated with colectomy in the United States. J Manag Care Pharm 2009; 15: 485–494.
9 Asgeirsson T, El-Badawi KI, Mahmood A, Barletta J, Luchtfeld M, Senagore AJ. Postoperative ileus: it costs more than you expect. J Am Coll Surg 2010; 210: 228–231.
10 Chambers D, Paton F, Wilson P, Eastwood A, Craig D, Fox D et al. An overview and methodological assessment of systematic reviews and meta-analyses of enhanced recovery programmes in colorectal surgery. BMJ Open 2014; 4: e005014.
11 Greco M, Capretti G, Beretta L, Gemma M, Pecorelli N, Braga M. Enhanced recovery program in colorectal surgery: a meta-analysis of randomized controlled trials. World J Surg 2014; 38: 1531–1541.
12 Adamina M, Kehlet H, Tomlinson GA, Senagore AJ, Delaney CP. Enhanced recovery pathways optimize health outcomes and resource utilization: a meta-analysis of randomized controlled trials in colorectal surgery. Surgery 2011; 149: 830–840.
13 Møller C, Kehlet H, Friland SG, Schouenborg LO, Lund C, Ottesen B. Fast track hysterectomy. Eur J Obstet Gynaecol Reprod Biol 2001; 98: 18–22.
Laxatives after abdominal surgery

14 Lu D, Wang X, Shi G. Perioperative enhanced recovery programmes for gynaecological cancer patients. Cochrane Database Syst Rev 2015; (3):CD008239.

15 Bond-Smith G, Belgaumkar AP, Davidson BR, Gurusamy KS. Enhanced recovery protocols for major upper gastrointestinal, liver and pancreatic surgery. Cochrane Database Syst Rev 2016; (2):CD011382.

16 Visioni A, Shah R, Gabriel E, Atwood K, Kukar M, Nurkin S. Enhanced recovery after surgery for noncolorectal surgery?: a systematic review and meta-analysis of major abdominal surgery. Ann Surg 2018; 267: 57–65.

17 Chapuis PH, Bokey L, Keshava A, Rickard MJFX, Stewart P, Young CJ et al. Risk factors for prolonged ileus after resection of colorectal cancer: an observational study of 2400 consecutive patients. Ann Surg 2013; 257: 909–915.

18 Kronberg U, Kiran RP, Soliman MS, Hammel JP, Galway U, Coffey JC et al. A characterization of factors determining postoperative ileus after laparoscopic colectomy enables the generation of a novel predictive score. Ann Surg 2011; 253: 78–81.

19 Millan M, Biondo S, Fraccalvieri D, Frago R, Golda T, Kreisler E. Risk factors for prolonged postoperative ileus after colorectal surgery. World J Surg 2012; 36: 179–185.

20 Chapman SJ, Wells CI. Challenges in ileus research. Colorectal Dis 2018; 20: 639.

21 Boeckxstaens GE, de Jonge WJ. Neuroimmune mechanisms in postoperative ileus. Gut 2009; 58: 1300–1311.

22 Gustafsson UO, Scott MJ, Hubner M, Nygren J, Demartines N, Francis N et al. Guidelines for perioperative care in elective colorectal surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations: 2018. World J Surg 2019; 43: 659–695.

23 Chapman SJ, Pericleous A, Downey C, Jayne DG. Postoperative ileus following major colorectal surgery. Br J Surg 2018; 105: 795–810.

24 Dudi-Venkata NN, Kroon HM, Bedrikovetski S, Moore JW, Sammour T. Systematic scoping review of enhanced recovery protocol recommendations targeting return of gastrointestinal function after colorectal surgery. ANZ J Surg 2020; 90: 41–47.

25 Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.

26 van Bree SHW, Bemelman WA, Hollmann MW, Zwinderman AH, Matteoli G, Temma SE et al. Identification of clinical outcome measures for recovery of gastrointestinal motility in postoperative ileus. Ann Surg 2014; 259: 708–714.

27 Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD et al.; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.

28 Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014; 14: 135.

29 Melsen WG, Bootsma MC, Rovers MM, Bonten MJM. The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses. Clin Microbiol Infect 2014; 20: 123–129.

30 McNeanly A, Pereovich M, Glantz C, Ducey EF, Flynn MK, Buchsbaum G. Bowel function after minimally invasive urogynecologic surgery: a prospective randomized controlled trial. Female Pelvic Med Reconstr Surg 2012; 18: 82–85.

31 Andersen J, Christensen H, Pachler JH, Hallin M, Thaysen HV, Kehlet H. Effect of the laxative magnesium oxide on gastrointestinal functional recovery in fast-track colonic resection: a double-blind, placebo-controlled randomized study. Colorectal Dis 2012; 14: 776–782.

32 Hansen CT, Sorensen M, Moller C, Ottesen B, Kehlet H. Effect of laxatives on gastrointestinal functional recovery in fast-track hysterectomy: a double-blind, placebo-controlled randomized study. Am J Obstet Gynecol 2007; 196: 311.e1–e7.

33 Hendry PO, van Dam RM, Bukkems SFW, McKeown DW, Parks RW, Preston T et al.; Enhanced Recovery After Surgery (ERAS) Group. Randomized clinical trial of laxatives and oral nutritional supplements within an enhanced recovery after surgery protocol following liver resection. Br J Surg 2010; 97: 1198–1206.

34 Wiriyakosol S, Kongdan Y, Euanorasetr C, Wacharachaisurapol N, Lertsitichai P. Randomized controlled trial of bisacodyl suppository versus placebo for postoperative ileus after elective colectomy for colon cancer. Asian J Surg 2007; 30: 167–172.

35 Zingg U, Miskovic D, Pasternak I, Meyer P, Hamel CT, Metzger U. Effect of bisacodyl on postoperative bowel motility in elective colorectal surgery: a prospective, randomized trial. Int J Colorectal Dis 2008; 23: 1175–1185.

36 Bampton PA, Dinning PG, Kennedy ML, Lubowski DZ, Cook IJ. Prolonged multi-point recording of colonic manometry in the unprepared human colon: providing insight into potentially relevant pressure wave parameters. Am J Gastroenterol 2001; 96: 1838–1848.

37 Rao SS, Sadeghi P, Beaty J, Kavlock R. Ambulatory 24-hour colonic manometry in slow-transit constipation. Am J Gastroenterol 2004; 99: 2405–2416.

38 Lin AY, Du P, Dinning PG, Arkwright JW, Kamp JP, Cheng LK et al. High-resolution anatomic correlation of cyclic motor patterns in the human colon: evidence of a rectosigmoid brake. Am J Physiol Gastrointest Liver Physiol 2017; 312: G508–G515.

39 Olsen O, Hakansson T, Forrest JI. Bisacodyl in the treatment of postoperative intestinal atony. Ugeskr Laeger 1985; 147: 3070–3071.
40 Kraus K, Fanning J. Prospective trial of early feeding and bowel stimulation after radical hysterectomy. *Am J Obstet Gynecol* 2000; 182: 996–998.

41 Fanning J, Yu-Brekke S. Prospective trial of aggressive postoperative bowel stimulation following radical hysterectomy. *Gynecol Oncol* 1999; 73: 412–414.

42 Basse L, Hjort Jakobsen D, Billesbolle P, Werner M, Kehlet H. A clinical pathway to accelerate recovery after colonic resection. *Ann Surg* 2000; 232: 51–57.

**Supporting information**

Additional supporting information can be found online in the Supporting Information section at the end of the article.